✦ LIBER ✦

Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

✍ Scribed by Katsuto Takenaka; Tetsuya Eto; Koji Nagafuji; Kenjiro Kamezaki; Yayoi Matsuo; Goichi Yoshimoto; Naoki Harada; Maki Yoshida; Hideho Henzan; Ken Takase; Toshihiro Miyamoto; Koichi Akashi; Mine Harada; Takanori Teshima; for Fukuoka Blood and Marrow Transplant Group (FBMTG)

Book ID: 107618700
Publisher: Carden Jennings Publishing
Year: 2009
Tongue: English
Weight: 215 KB
Volume: 89
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-008-0249-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Valganciclovir is safe and effective as

Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation

✍ Ayala, E; Greene, J; Sandin, R; Perkins, J; Field, T; Tate, C; Fields, K K; Gold 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

Validation of a DNAemia cutoff for preem

Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients

✍ Gerna, G; Lilleri, D; Caldera, D; Furione, M; Zenone Bragotti, L; Alessandrino, 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 160 KB

The immunosuppressive effect of human cy

The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantation

✍ Giebel, S; Maccario, R; Lilleri, D; Zecca, M; Avanzini, M A; Marconi, M; Di Cesa 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 228 KB

What is the optimal dosage of valgancicl

What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?

✍ Candoni, A; Simeone, E; Tiribelli, M; Pipan, C; Fanin, R 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 78 KB

Oral valganciclovir as pre-emptive thera

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

✍ van der Heiden, P L J; Kalpoe, J S; Barge, R M; Willemze, R; Kroes, A C M; Schip 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 140 KB

Clinically-based determination of safe D

Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients

✍ Daniele Lilleri; Fausto Baldanti; Marta Gatti; Francesca Rovida; Luca Dossena; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract Transplantation Centers using human cytomegalovirus (HCMV) antigenemia‐based preemptive therapy will need to replace in the near future the antigenemia assay with a more standardized and automatable assay, such as a molecular assay quantifying HCMV DNA in blood (DNAemia). Thus, in view